MARKET

ICVX

ICVX

Icosavax, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

28.99
+0.89
+3.17%
After Hours: 28.99 0 0.00% 16:00 09/24 EDT
OPEN
27.70
PREV CLOSE
28.10
HIGH
29.43
LOW
25.68
VOLUME
77.65K
TURNOVER
--
52 WEEK HIGH
49.99
52 WEEK LOW
21.70
MARKET CAP
1.14B
P/E (TTM)
-51.2100
1D
5D
1M
3M
1Y
5Y
48 Biggest Movers From Friday
Gainers Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) shares jumped 135.4% to settle at $5.32 on Friday. The stock possibly traded higher following favorable data results by AstraZeneca for patients with unresectable, stage 3 non-small cell lung cancer.
Benzinga · 5d ago
Icosavax Q2 EPS $(2.86) Down From $(2.45) YoY
Icosavax (NASDAQ:ICVX) reported quarterly losses of $(2.86) per share. This is a 16.73 percent decrease over losses of $(2.45) per share from the same period last year.
Benzinga · 09/13 20:10
-- Earnings Flash (ICVX) ICOSAVAX Reports Q2 Loss $-2.86
MT Newswires · 09/13 16:28
Icosavax Appoints Elizabeth Bekiroğlu to General Counsel
SEATTLE, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today announced the appointment ...
GlobeNewswire · 09/10 12:00
Icosavax Starts Trial of Pneumonia Virus Vaccine
MT Newswires · 09/09 12:38
Icosavax Initiates Phase 1/1b Trial of VLP Vaccine Candidate Against Respiratory Syncytial Virus
 Icosavax, Inc. (NASDAQ:ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today announced the initiation of a
Benzinga · 09/09 12:02
60 Biggest Movers From Yesterday
Gainers Trillium Therapeutics Inc. (NASDAQ: TRIL) shares jumped 188.8% to close at $17.59 on Monday after the company agreed to be acquired by Pfizer for $18.50 per share, implying an equity value of $2.26 billion.
Benzinga · 08/24 09:11
Benzinga's Top Ratings Upgrades, Downgrades For August 23, 2021
Upgrades JP Morgan upgraded the previous rating for Pearson PLC (NYSE:PSO) from Neutral to Overweight. The current stock performance of Pearson shows a 52-week-high of $12.38 and a 52-week-low of $6.13. Moreover, at the end of the last trading period, the...
Benzinga · 08/23 14:20
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ICVX. Analyze the recent business situations of Icosavax, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ICVX stock price target is 50.00 with a high estimate of 50.00 and a low estimate of 50.00.
EPS
Institutional Holdings
Institutions: 0
Institutional Holdings: 0
% Owned: 0.00%
Shares Outstanding: 39.39M
TypeInstitutionsShares
Increased
0
0
New
0
0
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Chairman/Director
Tadataka Yamada
Chief Executive Officer/Director/Primary Contact
Adam Simpson
Chief Scientific Officer
Douglas Holtzman
General Counsel
Elizabeth Bekiroglu
Executive Officer
Cassia Cearley
Executive Officer
Niranjan Kanesa-Thasan
No Data
About ICVX
Icosavax Inc. is a biopharmaceutical company. The Company uses its virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with a focus on respiratory diseases. Its VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens. The Company's pipeline includes vaccine candidates targeting viral causes of pneumonia. Its vaccine candidate IVX-A12 is a bivalent candidate, or a mixture of two different VLP candidates. IVX-A12 combines IVX-121, a vaccine candidate designed to target respiratory syncytial virus (RSV), and IVX-241, a vaccine candidate designed to target human metapneumovirus (hMPV). The Company is also developing two severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine candidates, IVX-411 and IVX-421, with a Phase I/II clinical trial of IVX-411.

Webull offers kinds of Icosavax Inc stock information, including NASDAQ:ICVX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ICVX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ICVX stock methods without spending real money on the virtual paper trading platform.